scholarly journals Prognostic Value of Circulating IGFBP2 and Related Autoantibodies in Children with Metastatic Rhabdomyosarcomas

Diagnostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 115
Author(s):  
Elena Poli ◽  
Angelica Zin ◽  
Manuela Cattelan ◽  
Lucia Tombolan ◽  
Ilaria Zanetti ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Prognostic Markers ◽  
Humoral Response ◽  
Healthy Controls ◽  
Plasma Samples ◽  
Event Free Survival ◽  
Plasma Biomarker ◽  
Free Survival ◽  
Blood Samples ◽  
Specific Humoral Response

Insulin-like growth factor-binding protein 2 (IGFBP2) is a tumor-associated protein measurable in patients’ biopsies and blood samples. Increased IGFBP2 expression correlates with tumor severity in rhabdomyosarcoma (RMS). Thus, we examined the plasmatic IGFBP2 levels in 114 RMS patients and 15 healthy controls by ELISA assay in order to evaluate its value as a plasma biomarker for RMS. Additionally, we looked for the presence of a humoral response against IGBFP2 protein measurable by the production of anti-IGFBP2 autoantibodies. We demonstrated that both circulating IGFBP2 protein and autoantibodies were significantly higher in RMS patients with respect to controls and their combination showed a better discriminative capacity. IGFBP2 protein identified metastatic patients with worse event-free survival, whereas both IGFBP2 and anti-IGFBP2 antibodies negatively correlated with overall survival. Our study suggests that IGFBP2 and anti-IGFBP2 antibodies are useful for diagnostic and prognostic purposes, mainly as independent negative prognostic markers in metastatic patients. This is the first study that reports a specific humoral response in RMS plasma samples and proves the value of blood-based biomarkers in improving risk assessment and outcome of metastatic RMS patients.

scholarly journals The expression of an intraspecific aggressive reaction in the face of a stressor agent alters the immune response in rats

2005 ◽  
Vol 65 (2) ◽  
pp. 203-209 ◽  
Author(s):  
J. M. Barreto-Medeiros ◽  
E. G. Feitoza ◽  
K. Magalhães ◽  
R. R. da Silva ◽  
F. M. Manhães-de-Castro ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Humoral Response ◽  
Aggressive Response ◽  
Control Group ◽  
Blood Samples ◽  
Humoral Immune ◽  
The Face ◽  
Intraspecific Aggressiveness ◽  
Specific Humoral Response

The repercussion on the immune response of the expression of intraspecific aggressiveness in the face of a stressor agent was investigated in rats. Ninety-day-old animals were divided into three groups: the control group (only immunological measurements were performed), the foot-shock (FS) (animals individually receiving FS), and the intraspecific aggressive response (IAR) group (animals receiving FS and presenting IAR). For immunological measurements, blood samples were collected promptly at 7 and 15 days after FS or IAR. The FS reduced the total leukocyte amount presented. However, aggressiveness triggered not only reduction of the leukocytes, but also lymphocyte decrease and neutrophil increase. Moreover, an elevation in total leukocytes associated with an increase in the humoral immune response was also observed one week after IAR. In this study, the expression of intraspecific aggressiveness in the face of a stressor seemed to activate the immune system and to potentiate the antigen specific humoral response.

scholarly journals 1046 Prognostic value of cardiac magnetic resonance imaging in mitral valve prolapse

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
A L Bouttier ◽  
A Jobbe-Duval ◽  
C Cueff ◽  
N Piriou ◽  
P Jaafar ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Magnetic Resonance ◽  
Mitral Regurgitation ◽  
Prognostic Value ◽  
Severe Mitral Regurgitation ◽  
Event Free Survival ◽  
Arterial Embolism ◽  
Free Survival ◽  
Lv Mass ◽  
Cmr Imaging

Abstract Background Mitral valve prolapse (MVP) is a frequent pathology that can be complicated by mitral regurgitation, heart failure, rhythm disorders, arterial embolism and death. The aim of this study was to evaluate the prognostic interest of ventricular volumes, right ventricular ejection fraction (RVEF) and late gadolinium enhancement (LGE) assessed by cardiac magnetic resonance (CMR) imaging on cardiovascular morbi-mortality in a cohort of patients with MVP Methods We examined the prognostic value of CMR imaging in 237 patients with MVP (no to severe mitral regurgitation) included between 2010 and 2019. All patients underwent a comprehensive echocardiography. The main endpoint was a composite endpoint of cardiovascular death, heart failure, new onset atrial fibrillation, arterial embolism. Results Among the 237 patients (63% male), 97 (41%) had LGE (75 myocardial wall, 10 papillary muscle tip and 12 both locations). Factors associated with LGE in multivariable analysis were age (OR 1.02, P = 0.037), left ventricular (LV) mass (OR 1.01, P = 0.008) and pulmonary artery systolic pressure (PAPS, OR 1.02, P = 0.069). Follow-up was censored at the time of surgery or percutaneous repair. In univariate analysis NYHA class, LV mass, left atrial volume, PAPS, LV end-diastolic and end-systolic volumes, chordal rupture and MR degree were associated with outcome. RVEF and biventricular dysfunction (LV EF < 60% and RV EF < 40%) were also associated with impaired event-free survival (36.0 ± 17.0% vs 65.4± 5.8%, P = 0.019). Finally, LGE was associated with a decreased event-free survival (55.6 ± 9.9% vs 70.7± 6.9%, P = 0.002). In multivariablee analysis, moderate to severe mitral regurgitation (HR : 2.14 [1.44-3.19], P < 0.0001) and the presence of LGE were predictors of impaired event-free survival (HR : 2.12 [1.08-4.16], P = 0.003). Conclusion CMR imaging provides additional prognostic information to echocardiography in the study of MVP. Myocardial fibrosis of the left ventricle and right ventricular function as assessed by CMR imaging are predictors of cardiovascular morbidity and mortality in MVP.

An Improved Prognostic Parameter for Non-Hodgkin's Lymphoma Based on the Combination of Three Serum Tumor Markers

2008 ◽  
Vol 23 (4) ◽  
pp. 207-213
Author(s):  
W. Gui ◽  
T. Wang ◽  
J. Wang ◽  
L. Wang ◽  
J. He ◽  
...  
Keyword(s):  
Overall Survival ◽  
Tumor Markers ◽  
Prognostic Value ◽  
Hodgkin’S Lymphoma ◽  
Survival Rates ◽  
Hodgkin's Lymphoma ◽  
Event Free Survival ◽  
Free Survival ◽  
Serum Tumor Markers ◽  
Non Hodgkin's Lymphoma

We aimed to evaluate the prognostic value of the combination of three serum tumor markers (LDH, β2-M and CA 125) in patients with non-Hodgkin's lymphoma (NHL). Clinical and pathological variables including the levels of these markers were measured in 415 NHL patients. Statistical analysis showed that increased levels of all three markers were associated with stage, B symptoms, effusions, bone marrow involvement, and International Prognostic Index (IPI) in NHL patients (p<0.05). Overall survival and event-free survival rates were associated not only with LDH but also with β2-M and CA125 (p<0.001). Response to treatment and overall survival rates were different in three groups with elevated LDH; in particular, the combination of three or two elevated markers seemed to identify a group of patients at higher risk of treatment failure and/or relapse than the group with a high LDH level only. Furthermore, multiple Cox regression analysis showed that IPI score complemented by the additional serum markers β2-M and CA125 was a better prognosticator of overall and event-free survival than LDH alone. This result suggests that if the combination of three elevated serum tumor markers is included as a parameter in the IPI instead of LDH alone, the prognostic value of IPI can be improved.

scholarly journals The Potential Role of Ferritin in Relation to Inflammatory and Metabolic Syndrome Biomarkers in Patients Undergoing Total Joint Arthroplasty of the Hip or Knee

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4560-4560
Author(s):  
Christopher Wanderling ◽  
Jeffrey Liles ◽  
Peter Carlsgaard ◽  
Jennifer Saluk ◽  
Daneyal Syed ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Standard Deviation ◽  
Total Joint Arthroplasty ◽  
Joint Arthroplasty ◽  
Iron Regulation ◽  
Healthy Controls ◽  
Plasma Samples ◽  
Blood Samples ◽  
C Peptide ◽  
Pai 1

Abstract Introduction: Maintaining proper iron regulation systemically is crucial in preserving systemic homeostasis. Ferritin is known to be a key component in this regulation by acting as a buffer via the controlled binding and releasing of iron. Ferritin is not only crucial in iron regulation, but it has also been observed to be a biomarker of inflammation. Considering this observation, it may be possible that ferritin plays a role in the pathogenesis of degenerative joint diseases (DJD). It has been identified that patients who had underwent total joint arthroplasty (TJA) procedure had increased serum levels of ferritin both pre-operatively and post-operatively. The rate of TJA procedures has been progressively increasing and it is projected that TJA procedures will increase to over 4 million procedures performed by 2030. In consideration of this observation, it is becoming increasingly important to gain a more comprehensive understanding in the pathology of DJD that require TJA procedure. The aim of this study is to examine the levels of ferritin in TJA patients pre-operatively and compare this level with those of other inflammatory and metabolic syndrome biomarkers in the patient samples while comparing the ferritin measurement to that of healthy controls. Study Design and Methods: After approval of the Institutional Review Board (IRB), pre-operative day one and post-operative day one blood samples of 45 TJA patients who underwent total knee arthroplasty (TKA) or total hip arthroplasty (THA) procedure were obtained as de-identified samples. Blood samples were collected into tubes containing 3.2% (0.109M) sodium citrate, plasma was then isolated. Control citrated plasma samples from non-smoking, drug-free, volunteers (age 18-35 years old) were obtained from from a certified vendor (George King Biomedical, Overland Park, KS). Plasma samples were stored at -80O C. The plasma samples were profiled for ferritin, C-peptide, insulin, IL-6, resistin, IL-1a, and PAI-1 utilizing a biochip array technology (RANDOX, Antrim, UK). All individual results were compiled as mean+1 SD and are summarized in the following table. The Mann-Whitney U test and the Spearman correlation test were used to analyze patient and control samples. Results: Table. Normal Mean + standard deviation Pre-op Mean + standard deviation Post-op Mean + standard deviation Ferritin (ng/ml) 68.44±74.23 125.0±121.0 73.79±71.29 C-peptide (ng/ml) 3.22±2.577 2.65±2.986 3.40±3.64 IL-6 (pg/ml) 0.818±0.5228 27.18±41.18 55.69±38.74 Resistin (ng/ml) 2.49±0.7406 5.34±4.976 6.39±4.95 Insulin (uIU/ml) 20.77±19.01 37.75±82.58 41.39±77.53 IL-1a (pg/ml) 0.418±0.1507 0.663±0.7824 1.29±1.39 PAI-1 (ng/ml) 3.21±4.127 14.98±9.836 17.89±11.58 There were significant increases in pre-operative levels of ferritin (p=0.0305), IL-6 (p<0.0001), resistin, (p<0.0001), IL-1a (p=0.0483), and PAI-1 (p<0.0001). There were insignificant alterations in the levels of C-peptide (decreased) and insulin (increased) in the pre-operative samples when compared with the healthy controls. Pre-operative correlations were observed between ferritin and each of the measured biomarkers; C-peptide (p=0.0043, R=0.324), IL-6 (p=0.00034, R=0.40), resistin (p=0.00043 R=0.394), insulin (p=0.00054, R=0.388), IL-1a (p=0.0256, R=-0.256), and PAI-1 (p<0.0001, R=0.460). Post-operative correlations were observed between ferritin and C-peptide (p=0.0008, R=0.529), as well as Insulin (p=0.0037, R=0.372). There was a correlation observed between pre-operative and post-operative levels of ferritin (p=0.0035, R=0.4943). Interestingly, the post-op values for ferritin dramatically decreased despite an increase in all other inflammatory and metabolic biomarkers. Conclusions: Understanding the factors that may affect ferritin regulation in TJA patients may be helpful in the management of DJD. Profiling inflammatory and metabolic syndrome biomarkers, including ferritin, may provide dynamic management options in the future that not only reduce adverse outcomes in these patients but also control the progression of degenerative processes. Disclosures No relevant conflicts of interest to declare.

scholarly journals Prognostic markers of lymphoblastic lymphoma

2020 ◽  
Vol 19 (4) ◽  
pp. 198-204
Author(s):  
E. V. Volchkov ◽  
Yu. V. Olshanskaya ◽  
N. V. Myakova
Keyword(s):  
Prognostic Markers ◽  
Lymphoblastic Leukemia ◽  
Survival Rates ◽  
Risk Groups ◽  
Lymphoblastic Lymphoma ◽  
Biological Factors ◽  
Event Free Survival ◽  
Treatment Protocols ◽  
Free Survival ◽  
New System

Lymphoblastic lymphoma (LBL) is the second most common non-Hodgkin's lymphoma in childhood. According to modern concepts LBL and acute lymphoblastic leukemia (ALL) are considered as manifestations of the same disease given the similar morphological substrate of the tumor – T and B lymphoblasts. The standard for the treatment of LBL is currently ALL-like riskadapted treatment protocols that allow achieving overall and event-free survival rates of 80–90%. The division into risk groups is based on the stage of the disease and the response to induction therapy. However, the problem of relapse/refractory course of the disease remains a serious problem due to the lack of sufficiently effective therapeutic options. Currently, there is a sufficient amount of clinical data that reliably shows that a number of molecular biological factors can be used to create a new system of into risk groups stratification of patients with LBL. This review focuses on the analysis of various factors that may be responsible for the prognosis of LBL in children.

scholarly journals Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

Cancer ◽  
2017 ◽  
Vol 123 (19) ◽  
pp. 3709-3716 ◽  
Author(s):  
Mariano Provencio ◽  
Ana Royuela ◽  
María Torrente ◽  
Marina Pollán ◽  
José Gómez-Codina ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Prognostic Value ◽  
Oncology Group ◽  
Event Free Survival ◽  
Free Survival ◽  
Study Report ◽  
Long Term Mortality

scholarly journals P1401 The prognostic value of the reduction of coronary flow velocity reserve in non-ischemic heart failure patients

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
C Borguezan Daros ◽  
Q Ciampi ◽  
H Zanella ◽  
L Cortigiani ◽  
N Gaibazzi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Flow Velocity ◽  
Coronary Flow ◽  
Prognostic Value ◽  
Ischemic Heart Failure ◽  
Coronary Flow Velocity Reserve ◽  
Event Free Survival ◽  
Free Survival ◽  
Coronary Flow Velocity

Abstract OnBehalf Stress Echo 2020 study group of the Italian Society of Cardiovascular Imaging Background Coronary microvascular abnormalities determining a reduction of coronary flow velocity reserve (CFVR) have been described in patients (pts) with non-ischemic heart failure (HF). Aim To assess the prognostic value of CFVR in HF. Methods In a prospective, observational, multicenter study, we recruited 333 pts with angiographically normal coronary arteries: 105 patients with HF and preserved (&gt;50%) ejection fraction (HFpEF); 71 with HF and mid-range (40-50%) ejection fraction (HFmrEF); 157 with HF and reduced (&lt;40%) ejection fraction (HFrEF). All patients underwent vasodilator SE with dipyridamole (0.84 mg/kg) in 10 accredited laboratories of 5 countries (Argentina, Brazil, Italy, Mexico, Serbia). CFVR was calculated as the stress/rest ratio of diastolic peak flow velocity pulsed wave-Doppler assessment of LAD flow. In all patients we also assessed left ventricular contractile reserve (LVCR) based on force (systolic blood pressure/end-systolic volume) Abnormal cutoff values were ≤2.0 for CFVR and ≤1.1 for LVCR. All pts were followed-up. Results After a median follow-up time of 15 months, 78 events occurred: 36 hospital admissions for acute decompensated heart failure, 23 deaths, 16 worsening in NYHA functional class, 2 stroke and 1 late revascularization. Event-free survival was best in patients with preserved CFVR and LVCR and worst in pts with reduced CFVR and impaired LVCR, with intermediate values for patients with either one (CFVR or LVCR) abnormal results: see figure. A preserved CFVR was associated with a better 24-month event-free survival than reduced CFVR in a subset analysis in pts with HFpEF (HR = 16.2, 95% CI, 1.8-145.1, p = 0.001) and in HFrEF (HR = 3.06, 95% CI, 1.6-5.6, p &lt; 0.001). A multivariable analysis in the overall group of HF pts identified a reduced CFVR as the only independent predictor of event-free survival (HR = 3.455,95% CI 1.723-6.929). Conclusions A reduction in CFVR identifies a high risk subset in HF patients, outlining a shared role of coronary microvascular abnormalities as a marker and potential therapeutic target of HF, independently of underlying EF. Abstract P1401 Figure. Event-free survival based on CFVR-LVCR

scholarly journals The physiologic and prognostic value of regional longitudinal strain during dipyridamole stress echocardiography

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
RA Rosina Arbucci ◽  
DML Diego Maximiliano Lowenstein ◽  
AKS Ariel Karim Saad ◽  
MGR Maria Graciela Rousee ◽  
NG Natalio Gastaldello ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Stress Echocardiography ◽  
Longitudinal Strain ◽  
Event Free Survival ◽  
Private Company ◽  
Free Survival ◽  
Myocardial Infraction ◽  
Dipyridamole Stress Echocardiography ◽  
Dipyridamole Stress

Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Investigaciones Médicas, Cardiodiagnostic Background.  Regional apical longitudinal strain (RALS) allows to corroborate the diagnosis of regional wall motion abnormalities (RWMA) during dipyridamole stress echocardiography (DSE) on a quantitative basis but data on the prognostic value are missing. Objectives.  The to evaluate the physiologic correlates and prognostic value of RALS vs. RWMA during DSE. Methods.  In a single center, observational design we initially evaluated 150 patients (pts), mean age 68.3 ± 9.6 years, 50.7% men referred for DSE.  RALS was defined as the average of the four apical segments from the 3 apical views.  Any increase in the percentage of deformation was considered normal. Coronary flow velocity reserve (CFVR) was also assessed in mid-distal left anterior descending (LAD) coronary artery by pulsed-wave Doppler. Pts were divided into two groups (G). G1: patients with normal RALS, and G2: patients with abnormal RALS.  Major cardiovascular event was considered to be: cardiovascular death, acute myocardial infraction (AMI), stroke or needs for revascularization after 3 months All patients were followed-up. Results. RALS success rate was 94.6% (142 pts), since 8 pts were excluded for inadequeate window. Eighty-seven patients (61.3%) were included in G1 and 55 (38.7%) pts in G2. The mean follow-up was 36 ± 0.93 months. There were no differences in the resting RALS between the G1 and G2 (-22.3% ± 3.3 vs -21.25% ± 4.9, p = NS), but significant differences in the peak dipyridamole effect (-26.3% ± 4.2 vs -18.8% ± 4.1, p &lt; 0.001). Pts G1  showed less RWMA  than pts G2 (G1 3.4% vs  G2 90 %), p &lt; 0.001) and higher CFVR (G1= 2.6 ± 0.5 vs G2 = 1.6 ± 0.4, p &lt; 0.001). Adequeate CFVR showed high concordance with the increase in RALS evaluated  by Kappa Index 0.95, p 0.001 (Pts G1= 98.9% vs pts G2= 96.4%).  In the long-term follow up, 24 pts experienced events: 3 deaths, 3 non-fatal myocardial infarctions, 2 stroke and 16 late revascularizations. Pts with normal RALS had a better event-free survival (G1= 90.8% vs G2 = 70.9%, log Rank p &lt; 0.007, HR: 2.92; 95% CI: 1.27-6.68, p 0.011) (figure 1). In the multivariate analysis of logistic regression, adjusted for age, the RALS was an independent predictor of event. In G2 no significant differences were detected in event free survival in pts with and without visual dyssynergies during DSE (73.7 vs 67.7, respectively (p = ns) Conclusions. A mismatch between RALS and visually assessed RWMA occurs in a significant proportion of patients, and RALS is better correlated to physiologic (CFVR) and prognostic standards. Abnormal RALS during DSE predicted worse outcome, regardless of the RWMA.  Quantitative stress echocardiography is possible feasible and useful during DSE. Abstract Figure. RALS in DSE and Event Free Survival

scholarly journals Prognostic value of left ventricular ventricular dyssynchrony in left bundle branch block patients

2021 ◽  
Vol 22 (Supplement_3) ◽  
Author(s):  
C Cortes ◽  
EN Aramayo G ◽  
PE Barboza ◽  
EM Claros ◽  
MA Embon
Keyword(s):  
Left Bundle Branch Block ◽  
Lower Risk ◽  
Prognostic Value ◽  
Gated Spect ◽  
Left Ventricular ◽  
Spect Imaging ◽  
Event Free Survival ◽  
Bundle Branch Block ◽  
Free Survival

Abstract Funding Acknowledgements Type of funding sources: None. Background Patients with left bundle branch block (LBBB) patterns on the electrocardiogram include a heterogeneous group of patients with different prognosis and some of them with or without left ventricular mechanical dyssynchrony (LVMD). LVMD obtained by gated technetium 99m single photon emission computed tomography (SPECT) imaging could be an early tool to detect myocardial damage, identifying a high risk group. Purpose The aim of this study was to assess the prognostic value of LVMD in LBBB patients. Methods Five hundred and eighty consecutive patients with LBBB were referred for gated SPECT from August 2011 to June 2019. Phase analysis parameters Standard deviation (SD) and histogram bandwidth (HB) were obtained in rest gated SPECT imaging. LVMD was defined as the upper limit of the highest normal for phase analysis results in our control patients mean values plus two standard deviations (SD ≥ 21° or HB ≥ 67°). Follow up was performed by telephone contact or medical history review. Hard endpoint was all-cause death. Event-free survival curves were obtained. Univariate and multivariate regression analysis were performed. Results LVMD was observed in 254 (44%) patients. Compared to non LVMD patients had: similar age (67.68 ± 11.01 vs. 67.2 ± 10.3 y; p NS), more male (75.2% vs 39.6%), more hypertension (75.2% vs. 66.8%), more diabetes (22.8% vs. 13%) and more smoking history (31.9% vs. 23.7%) all p &lt;0.05. A total of 495 patients completed the follow up (mean 29.8 ± 25.8 months). Fourteen patients died (2.8%), 12 had LVMD. Fig 1 shows Kaplan-Meier curve of event-free survival in relation to LVMD. Variables associated with all-cause death in the univariate analysis were: Score Rest Summed ≥ 4 (p 0.02), LV ejection fraction ≤ 35% (p &lt; 0.01), diabetes (p 0.03) and LVMD (p &lt;0.01). The absence of LVMD was a predictor of the lower risk of all-cause death in the multivariate analysis (adjusted hazard ratio: 0.13, 95% confidence interval: 0.03- 0.56; p &lt; 0.01). Conclusion In our population of patients with LBBB, the absence of LVMD assessed by gated SPECT imaging identifies patients with lower risk of hard adverse events.

Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17521-e17521
Author(s):  
Yecai Huang ◽  
Mei Feng ◽  
Qiao He ◽  
Peng Xu ◽  
Jinyi Lang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Metastatic Lymph Node ◽  
Cochrane Library ◽  
Study Quality ◽  
Event Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
Fdg Pet Ct

e17521 Background: Nasopharyngeal carcinoma (NPC) is a special subtype of head and neck cancer (HNC), there is no highly specific prognostic parameters for NPC. Prognostic value of pretreatment 18F-PET-CT in NPC patient has controversial conclusion. Methods: The prospective and retrospective observational trails which used the 18F-FDG PET to predict the prognosis of the NPC patients were searched in MEDLINE, EMBASE, Cochrane library, CBM, CNKI and VIP (inception to July 2016). Two authors independently assessed study quality and extracted data. Event-free survival (EFS) was considered as the primary endpoint and overall survival rate (OS) was considered as the secondary endpoint. Results: 14 studies and 1,134 patients were included in our analysis. The HR (Hazard ratio) of SUVmax-T, MTV-T and TLG-T for EFS was 1.71 (95% CI, 1.02-2.86, p= 0.04), 2.38 (95%CI 1.53-3.70, p= 0.0001) and 1.65 (95%CI 0.76-3.59, p= 0.21) respectively. Among studies including TLG-T, those with a fixed SUV of 2.5 had an HR 3.55 (95% CI, 1.42–8.84, p= 0.007). The HR of SUVmax-T and MTV-T for OS was 2.19 (95%CI, 1.47-3.27, p= 0.0001) and 2.69 (95% CI, 1.01-7.17, p =0.05). Among studies including MTV-T, those with a fixed SUV of 2.5 had an HR of 4.07 (95% CI, 2.22–7.46, p< 0.00001). Test for predictive value of pretreatment SUVmax-LN, MTV-LN and TLG-LN for EFS and OS showed no significant results ( p> 0.05). Conclusions: We suggested thatSUVmax, MTV and TLG (with a fixed SUV of 2.5) of primary tumor before treatment may be the independent prognostic factors for NPC patients, while SUVmax, MTV and TLG of metastatic lymph node are not.

Sign in / Sign up

Export Citation Format

Share Document